To examine the frequency and spectrum of diseases associated with isolated reduction in the diffusing capacity of lung for carbon monoxide (DLCO).
PATIENTS AND METHODS:
We retrospectively identified all potentially dyspneic patients who had pulmonary function tests (PFTs) performed at the Mayo Clinic in Jacksonville, Fla, between January 1, 1990, and June 30, 2000 , that showed reduced DLCO (<70% of predicted), normal lung volumes (total lung capacity and residual volume >80% and <120% of predicted, respectively), and airflow variables (forced expiratory volume in 1 second and forced vital capacity values >80% of predicted and forced expiratory volume in 1 second/forced vital capacity ratio >70% of predicted). Only patients who had also undergone chest computed tomography (CT) and echocardiography within 1 month of PFTs were studied.
RESULTS: Of the 38,095 patients who underwent PFTs during the study period, 179 (0.47%; 95% confidence interval [CI] , 0.40%-0.54%) had isolated DLCO abnormalities. The 27 patients (15.1%; 95% CI, 10.2%-21.2%) who had also undergone chest CT and echocardiography within 1 month of PFTs form the study cohort reported herein. Their mean DLCO was 50%±15% (95% CI, 45%-56%) with average normal pulse oxygen saturation at rest and mild hypoxemia with activity. Thirteen of the 27 patients (48%; 95% CI, 28.7%-68.1%) had underlying emphysema evident on CT. Eleven of these 13 patients had emphysema associated with a restrictive lung process. The 14 patients without emphysema had interstitial lung disease, pulmonary vascular disease, and other isolated findings. Six patients with combined emphysema and idiopathic pulmonary fibrosis accounted for the largest percentage (22%) of patients with isolated DLCO reduction. The mean ± SD smoking history of the 27 patients in the study cohort was 36±33 pack-years (range, 0-116 pack-years).
CONCLUSION: Dyspneic patients with respiratory symptoms and normal lung volumes and airflows associated with isolated reduction in DLCO should be evaluated for underlying diseases such as emphysema, with or without a concomitant restrictive process, and pulmonary vascular disease.
Mayo Clin Proc. 2007;82(1):48-54 ATS = American Thoracic Society; CHF = congestive heart failure; CI = confidence interval; CT = computed tomography; DLCO = diffusing capacity of lung for carbon monoxide; FEV 1 = forced expiratory volume in 1 second; FVC = forced vital capacity; HRCT = high-resolution CT; ILD = interstitial lung disease; IPF = idiopathic pulmonary fibrosis; PFT = pulmonary function test; SpO 2 = oxygen saturation measured by pulse oximetry; TLC = total lung capacity A nalysis of the diffusing capacity of lung for carbon monoxide (DLCO) is a clinically useful test of lung function. Frequently, it is used in the differential diagnosis of airway obstruction in current or former smokers. 1 In patients with a long-term smoking history and evidence of airways obstruction, normal DLCO suggests chronic bronchitis, and reduced DLCO suggests the presence of emphysema. 2 Abnormal DLCO levels are important in the differential diagnosis of patients with restrictive lung disease. The DLCO declines with restrictive lung disease because of the reduced area for gas exchange. Low DLCO in this setting suggests interstitial lung disease (ILD) or severe restriction. In patients with restrictive patterns on pulmonary function tests (PFTs) associated with a normal DLCO, the cause is most likely extrapulmonary, such as pleural disease, neuromuscular weakness, or kyphoscoliosis. [3] [4] [5] Patients with restriction attributable to extrapulmonary causes typically have a low-normal DLCO and elevated DLCO/alveolar volume using unadjusted predicted values and a normal DLCO and normal DLCO/alveolar volume when their predicted values are adjusted for lung volume. 6 Less commonly, reduced DLCO is discovered as an isolated abnormality in patients with otherwise normal lung function. This poses a challenge to the clinician who must identify the disease ultimately responsible for the abnormality from among various conditions with markedly different prognoses. Isolated reduced DLCO has been reported in a range of patients, from asymptomatic individuals who do not require additional medical evaluation 7 to those with severe pulmonary vascular or parenchymal lung disease. [8] [9] [10] [11] [12] [13] [14] [15] [16] Furthermore, patients with nonpulmonary diseases such as diabetes mellitus, hypothyroidism, and chronic renal failure and those with environmental dust exposures can also exhibit isolated reductions in DLCO. [17] [18] [19] [20] In patients with dyspnea, reduced DLCO has been reported to affect gas exchange.
Despite the recognition of this isolated physiologic abnormality in several clinical conditions, no large series describing patients with isolated abnormalities on diffusion capacity studies have been reported. The primary objective of this study was to investigate the frequency and spectrum of diseases associated with an isolated reduction in diffusion capacity in patients referred to a pulmonary function laboratory for diagnostic evaluation. A secondary objective was to further characterize underlying diseases among patients with isolated reduction in diffusion capacity, particularly in the context of patients with and without underlying emphysema.
PATIENTS AND METHODS
With Mayo Foundation Institutional Review Board approval, we retrospectively reviewed the pulmonary function database at the Mayo Clinic in Jacksonville, Fla, to identify complete PFTs performed between January 1, 1990, and June 30, 2000, in patients complaining of dyspnea. Pulmonary function studies included measurements of airflow, plethysmographic lung volumes, and DLCO (measured by the single-breath diffusion capacity method), with the aim of identifying patients with reduced DLCO but normal lung volumes and airflow (isolated reduced DLCO). In each confirmed case of isolated reduced DLCO, the medical record was reviewed to obtain the following data: age, sex, smoking history, presence of dyspnea, cough, or inspiratory dry crackles, and results of chest computed tomography (CT) and echocardiography (interpreted independently by an experienced thoracic radiologist [H.I.J.] and an echocardiographer who were unaware of the clinical and physiologic data). Results of tests ordered by the primary physician were reviewed, and the investigators agreed on a final clinical diagnosis. Because the presence of occult emphysema, ILD, or vaso-occlusive lung disease cannot be reliably excluded without examining a chest CT scan and an echocardiogram (to estimate right heart pressures), only those patients who had undergone chest CT and echocardiography within 1 month of their PFTs were included in the study.
PHYSIOLOGIC ASSESSMENT
All PFTs were performed with use of standard protocols. American Thoracic Society (ATS) guidelines 22 were used to determine acceptability using a calibrated pneumotachygraph (Medical Graphics; St Paul, Minn), and values were expressed as a percentage of the predicted values published by Miller et al. 23 Lung volumes were measured in a whole-body plethysmograph, and data were expressed as a percentage of published predicted values. 23 Diffusion capacity was typically measured 2 or more times if necessary, and the average of the 2 values meeting ATS guidelines was reported. All DLCO testing and calculations met ATS criteria for acceptability and repeatability. 24, 25 The patients' DLCO was expressed as a percentage of the predicted value, as described by Miller et al, 26 and adjusted for measured hemoglobin. The reproducibility of the instruments used in our PFT laboratories was checked by performing weekly biological quality control testing in 7 normal volunteers (laboratory technologists). The SD and coefficient of variation for DLCO were 1.0 and 4%, respectively. Reduced DLCO was clinically and arbitrarily defined by us as a value less than 70% of predicted. Lung volumes were considered normal when the total lung capacity (TLC) and the residual volume were more than 80% and less than 120% of predicted, respectively. Forced expiratory volume in 1 second (FEV 1 ) and forced vital capacity (FVC) values higher than 80% and an FEV 1 /FVC ratio higher than 70% of predicted defined the presence of normal airflow. Oxygen saturation measured by pulse oximetry (SpO 2 ) was determined at rest and using a 3-minute step exercise protocol with the patient breathing room air. A finger probe was used routinely. Recordings of SpO 2 resting values were obtained while the patients were seated and the pulse signal was steady. All patients were then instructed to exercise on a 9-inch (22.86-cm) step, stepping up and down for a maximum of 3 minutes, 1 step for each beat of a metronome set at a rate of 60 beats/min. Patients exercised while having their right hand on a railing and their left hand, with oximeter finger probe, held at waist height but not pressing against the abdomen. After 3 minutes, recordings of the ending saturation and pulse values were obtained. Only readings with good-quality pulse signals were recorded. With use of these criteria, we determined the frequency of isolated DLCO reduction in the pulmonary function database during the study period.
CHEST CT ASSESSMENT
Computed tomography was performed with use of a General Electric HiSpeed Advantage CT/T or CTi scanner (GE Medical Systems; Milwaukee, Wis), and the images were interpreted independently by an experienced thoracic radiologist (H.I.J.) who was unaware of the clinical and physiologic data. High-resolution CT (HRCT) scans were assessed at standard reference levels for the presence of ground-glass opacification, bronchiectasis, septal thickening, and honeycombing, the latter of which is defined as the presence of abnormal air spaces with a wall thickness of more than 2 mm. Bronchiectasis was defined by bronchial dilation, lack of normal bronchial tapering, and visibility of airways in the peripheral lung zones. Emphysema was diagnosed by the presence of areas of low attenuation, either focal unmarginated areas of low attenuation or bullae (air spaces >1 cm in diameter with wall thickness <1 mm). 
ECHOCARDIOGRAPHIC ASSESSMENT
Echocardiography was performed with use of a HewlettPackard Sonos 5500 echocardiography system (HewlettPackard, Andover, Mass). An echocardiographer who was unaware of the clinical and physiologic data interpreted the images independently. Systolic pulmonary arterial pressure was estimated by measuring the maximal velocity of the tricuspid regurgitant jet, which is incorporated into the Bernoulli equation, and adding a 2-dimensional estimation of right atrial pressure. 29 
FINAL DIAGNOSIS
In all cases, relevant clinical information and results of tests ordered by the primary physician were reviewed by the investigators. A final diagnosis was agreed on by a panel (J.F.A., D.A.Z., S.I.M.) using the diagnostic criteria outlined in Table 1 .
STATISTICAL ANALYSES
Continuous variables were expressed as mean ± SD. Statistically significant differences between continuous variables were determined by the Student t test. P<.05 was considered statistically significant. Categorical variables were described by frequencies and percentages.
RESULTS

PATIENT COHORT
Of the 38,095 patients who had pulmonary function studies archived in our database during the period of this study, 179 had an isolated reduction in DLCO (0.47%; 95% confidence interval [CI], 0.40%-0.54%). Twenty-seven of these 179 patients (15.1%; 95% CI, 10.2%-21.2%) had also undergone standard chest CT and echocardiography within 1 month of their PFTs, 16 of whom had also undergone HRCT.
CLINICAL DIAGNOSES AND PHYSIOLOGIC ASSESSMENTS
Final diagnosis, demographic data, PFT results, DLCO measurements, oxygen saturation values, and echocardiographic findings are presented in Table 2 . The mean ± SD DLCO was 50%±15% (95% CI, 45%-56%), with average normal pulse oxygen saturation at rest and mild hypoxemia with activity. Of the 27 patients with isolated DLCO, 13 (48%; 95% CI, 28.7%-68.1%) had a conclusive diagnosis of emphysema. This group included 1 patient with isolated emphysema (No. 13), 1 with associated pulmonary vascular disease (CREST syndrome [calcinosis cutis, Raynaud phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia] without ILD, No. 12), and 11 with association to a restrictive process. Among those 11 patients with a restrictive process and emphysema, 6 had findings of emphysema and IPF (No. 1-6), 2 had emphysema and amiodaroneinduced ILD (No. 8 and 9), and 1 had emphysema and hypersensitivity pneumonitis (No. 7). Two patients had emphysema and congestive heart failure (CHF) (No. 10 and 11). Four (15%) of the 27 patients had exclusively interstitial lung disease (2 had IPF, ILD of unknown origin, and 1 had radiation injury) (No. 14-17). Two patients (7%) had pulmonary vascular disease (1 with idiopathic pulmonary arterial hypertension and 1 with hepatopulmonary syndrome). The other patients were isolated cases with individual clinical diagnoses of CREST syndrome and rheumatoid arthritis but without ILD or pulmonary hypertension, cryptogenic organizing pneumonia, metastatic adenocarcinoma, lung cancer, CHF, and paralysis of the hemidiaphragm. Two had an active moderate smoking history, and 1 patient had no obvious abnormalities.
The diagnoses were based on typical chest CT findings in 13 patients (48%): 8 with emphysema and a concurrent ILD, 4 with ILD alone, and 1 with emphysema alone. Com- *Amio = amiodarone toxicity; Ca = cancer; CHF = congestive heart failure; COP = cryptogenic organizing pneumonia; CP = cor pulmonale; CREST = CREST syndrome; DLCO = diffusing capacity of lung for carbon monoxide; EF = ejection fraction; Emph = emphysema; FEV 1 = forced expiratory volume in 1 second; FVC = forced vital capacity; HP = hypersensitivity pneumonitis; HPPS = hepatopulmonary syndrome; ILD = interstitial lung disease; IPAH = idiopathic pulmonary arterial hypertension; IPF = idiopathic pulmonary fibrosis; mets = metastases; NA = not available; NSCC = non-small cell carcinoma; PASP = pulmonary artery systolic pressure; RA = rheumatoid arthritis; RV = residual volume; SpO 2 = oxygen saturation measured by pulse oximetry; TLC = total lung capacity. with idiopathic pulmonary arterial hypertension, and 1 with hepatopulmonary syndrome. Computed tomography suggested cryptogenic organizing pneumonia and hypersensitivity pneumonitis in 1 patient each, and lung biopsies confirmed the diagnoses. Five patients (19%) had unremarkable CT and echocardiographic findings. This information was relevant mainly to rule out serious lung or cardiovascular abnormalities. The 13 patients with emphysema were compared with the 14 patients without emphysema. Considering that most cases of isolated DLCO reduction occurred in patients with emphysema, commonly combined with ILD or pulmonary edema/CHF, the patients were divided into emphysema and nonemphysema groups for independent analysis. Detailed descriptions of the patients' characteristics are presented in Table 3 . The mean ± SD smoking history was 36±33 pack-years (range, 0-116 pack-years). The emphysema group had a significantly worse smoking history than the nonemphysema group (50±33 vs 24±29 pack-years; P=.04). The emphysema group also had worse DLCO than the nonemphysema group (43%±14% [95% CI, 35%-52%] vs 57%±12% [95% CI, 50%-64%]; P=.01), and they had worse pulmonary hypertension (estimated pulmonary systolic pressure, 62±31 vs 37±9 mm Hg; P=.02). Four patients in the emphysema group had an estimated pulmonary systolic pressure higher than 80 mm Hg with clinical evidence of cor pulmonale. Estimated pulmonary systolic pressures were lower among patients in the nonemphysema group, none of whom had an estimated pulmonary systolic pressure higher than 55 mm Hg. Both groups, patients with emphysema and those without emphysema, had normal average resting oxygen saturation levels (mean resting SpO 2 , 94%±5% vs 96%±2%) but mild hypoxemia during exercise (SpO 2 , 90%±6% vs 93%±4%).
At rest, 21 of the 27 patients had a normal SpO 2 (≥94%), 3 patients had mild to moderate hypoxemia (SpO 2 , 89%-93%), and 2 had severe oxygen desaturation (SpO 2 , ≤88%) ( Table 4) . No SpO 2 data were available for 1 patient. Eleven patients exhibited normal oxygenation during exercise. Four had mild to moderate reduction in SpO 2 with exercise, and 4 had severe exercise-induced oxygen desaturation. No exercise data were available for 8 patients.
Five of the 6 patients with severe oxygen desaturation at rest or during exercise were in the emphysema group, and 5 
*SpO 2 = oxygen saturation measured by pulse oximetry. *Values are expressed as mean ± SD. DLCO = diffusing capacity of lung for carbon monoxide; EF = ejection fraction; FEV 1 = forced expiratory volume in 1 second; FVC = forced vital capacity; PASP = pulmonary artery systolic pressure; RV = residual volume; SpO 2 = oxygen saturation measured by pulse oximetry; TLC = total lung capacity.
of the 7 patients with mild to moderate oxygen desaturation were in the nonemphysema group.
DISCUSSION
Measurements of DLCO assess the transfer of gases from the alveoli to red blood cells. The frequency and importance of reduced DLCO in patients with otherwise normal PFT results have not been systematically explored. This retrospective clinical study provides some insight into this situation. We have determined that in patients with dyspnea, an isolated reduction in DLCO is extremely rare (<1%). However, when present, it is commonly associated with emphysema and a concurrent restrictive process. Among the restrictive processes identified in our study population, IPF was the most frequently observed (22%). The discrepancy between DLCO and spirometric findings in patients with concomitant ILD/IPF and emphysema can be explained by the additive effect of these conditions on DLCO and their opposing effects on elastic recoil and therefore on lung volumes and flow rates.
As a result of smoking exposure or other irritants or a congenital deficiency of α 1 -antitrypsin, emphysema causes permanent enlargement of spaces distal to terminal bronchioles associated with destruction of alveolar walls but typically without obvious fibrosis. Destruction of lung parenchyma leads to loss of alveolar attachments to small airways, thus decreasing the normal lung elastic recoil, diminishing the ability of distal airways to remain open during expiration, and resulting in reduced airflow, which should be measurable during PFT. As the disease progresses, TLC increases as a result of pathologic enlargement of residual volumes. Because of the progressive destruction of alveolar structures, the DLCO is abnormally reduced. 30 Diffuse parenchymal lung disease or ILDs include a heterogeneous group of diseases related to occupational or environmental exposures (including cigarette smoking); these diseases may also occur in association with connective tissue diseases, or they may have an unknown etiology (idiopathic interstitial pneumonias, including IPF). Patients with ILD develop increased static elastic recoil, and their flow rates are often increased compared with given lung volumes. Lung volumes are typically restricted and progressively reduced. A decline in DLCO occurs as a result of contraction of the pulmonary capillary volume and by ventilation and perfusion abnormalities, and it may precede the reduction in lung volumes. 31 These opposing pathophysiologic mechanisms explain how patients with combined obstructive and restrictive lung diseases present with normal lung volumes and flows and at the same time have reduced DLCO, which may be greatly reduced. Recent ATS/ European Respiratory Society task force interpretive strategies for PFT 32 define reduction in DLCO as severe when it reaches a threshold of less than 40%, moderate when DLCO is 40% to 60%, and mild when DLCO ranges from higher than 60% to the lower limit of normal. According to that criteria, 70% of the 27 patients in our study population had a moderate or severe reduction in diffusion capacity (48% had moderate and 22% had severe reduction in DLCO). The patients in the emphysema group, most of whom had combined restrictive lung disease, had much worse diffusion capacity than the patients in the nonemphysema group: 92% (12/13) of the patients with emphysema had a moderate or severe reduction in DLCO, whereas only 50% (7/14) of patients without emphysema had this degree of abnormality.
Other investigators have also reported the combined presence of emphysema and pulmonary fibrosis that was observed in several of our cases. 33 The association of emphysema with an interstitial process such as pulmonary fibrosis or CHF could be the result of 2 coincidental processes occurring in the same patient. However, it is also likely that the association of 2 processes might represent the result of a common pathogenic mechanism such as smoking, inducing the presence of more than 1 process in the same patient. In support of the latter hypothesis is conclusive evidence that inflammation and fibrosis are present in patients with emphysema, and experimental studies have shown that the induction of lung injury by a single mechanism can produce emphysema, pulmonary fibrosis, or both. [34] [35] [36] [37] [38] Our study demonstrated that chest CT is of considerable value in the assessment of patients with isolated reduced DLCO, having the ability to discriminate various patterns of complex mixed obstructive and restrictive abnormalities. It should be the initial test for evaluating such patients. Echocardiography must also be included in their assessment. Although pulmonary vascular disease was a relatively uncommon finding in our study population, this test identified an important number of patients with severe pulmonary hypertension and some with left ventricular dysfunction and CHF that contributed to the reduction in DLCO.
Our study has the limitations inherent to retrospective analysis. Better definition of patients presenting with isolated abnormalities in diffusion capacity could be achieved by the systematic, protocol-oriented, and prospective evaluation of patients with reduction in diffusion capacity as their sole abnormality.
Another potential limitation of the study relates to the use of an FEV 1 /FVC ratio higher than 70% predicted to define the presence of normal airflow, which was considered the standard at the time this retrospective study was done. Guidelines such as the National Heart, Lung, and Blood Institute/World Health Organization Global Initiative for Chronic Obstructive Lung Disease Workshop summary 39 and the ATS/European Respiratory Society position paper on standards for diagnosis of chronic obstructive pulmonary disease define obstruction based on a fixed FEV 1 /FVC ratio, 40 a threshold value that is easy to use and apply. However, the use of a fixed FEV 1 /FVC ratio of less than 70% may exclude normal individuals of advanced age who could have been classified as having obstructive lung disease, and this threshold could potentially classify younger individuals as healthy when they have mild obstruction. The use of this fixed threshold value may produce discordant results in up to 16% of patients older than 74 years. 41 Conceivably, a small portion of elderly patients in our series may have been excluded from analysis because of the methods used to define normal individuals.
Predicted DLCO values could have been adjusted for lung volumes, but none of the patients in this series had a TLC lower than 80% predicted. According to Johnson, 6 at a lung volume of 80% predicted, DLCO declines to 93% predicted, and lung volume should decrease to 52% predicted for DLCO to decline to 80% predicted. Therefore, adjusting DLCO for lung volume would not have affected the results in this study. The selection of an arbitrary threshold of 70% or higher to define normal diffusion capacity, although practical and easy for clinicians to use, could have included some patients as having mild reduction in DLCO when they could have been classified as healthy if we had chosen another threshold for normal values.
Based on the results of this study, we conclude that a combination of fibrotic and emphysematous changes is the most frequent finding in patients with isolated reduced DLCO. However, other causes must be considered. The presence of isolated reduced DLCO necessitates additional investigation. In this regard, HRCT and echocardiography can establish the etiology in the majority of cases.
CONCLUSION
Reduction in DLCO in the context of normal lung volumes and airflows is an uncommon finding among patients evaluated for dyspnea. Isolated reduction in DLCO can frequently be explained by the association of emphysema with a restrictive lung process such as ILD or pulmonary edema/ CHF. Interstitial lung disease, pulmonary vascular conditions, or both explain most of the remaining cases. Isolated reduction in DLCO should prompt further clinical investigation and evaluation with HRCT and echocardiography.
